Related Experiment Video

Updated: Oct 23, 2025

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
08:30

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

14.3K

Very early glucose tolerance abnormalities in children with cystic fibrosis

Marie Blanquer1, Laurence Le Clainche1, Elise Bismuth2

  • 1University Robert Debré Hospital, Cystic Fibrosis Center, 48 bd Serurier, 75019 Paris, France.

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|August 21, 2021
PubMed

Insights

Early diabetes and glucose intolerance can occur in infants with cystic fibrosis (CF), sometimes resolving spontaneously. Diagnosis in this age group is challenging, impacting prognosis and nutritional status.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Pulmonology

Background:

  • Cystic Fibrosis (CF) is often associated with diabetes, worsening patient prognosis.
  • Abnormal glucose tolerance in CF correlates with reduced lung function and poor nutritional status.
  • Limited data exist on glucose tolerance abnormalities in infants with CF.

Observation:

  • Three infants with cystic fibrosis presented with abnormal glucose tolerance before one year of age.
  • Two infants were diagnosed with very early-onset diabetes before six months of age.
  • All patients experienced early Pseudomonas aeruginosa lung infections and suboptimal nutritional status.

Findings:

  • Despite early dysglycaemia, including very early diabetes, none required long-term insulin therapy.
  • Glycaemia levels spontaneously improved over time in all observed cases.
  • Early pulmonary infection and poor nutrition were common factors in these infants.

Implications:

  • This case series expands the understanding of early dysglycaemia spectrum in cystic fibrosis.
  • Highlights diagnostic challenges of glucose metabolism disorders in infants with CF.
  • Suggests potential for spontaneous glycaemic improvement in select young CF patients.

Keywords:
Glycaemic dysregulationInfantsScreeningVery early diabetes

More Related Videos

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test06:59

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

11.1K
Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model09:44

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Published on: March 5, 2022

3.1K

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
26.2K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
1.3K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
472
Overview of Carbohydrate Metabolism01:19

Overview of Carbohydrate Metabolism

Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
2.3K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
328
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
33.2K